FirstWord

FirstWord is a major healthcare intelligence provider worldwide. The customers are offered upscale reports on various sectors of pharmaceutical industry. Research is carried out by best specialists in pharma market who ensure the clients with unique data, deep insight into the issue, latest events and new technologies.

The experts have access to reliable and abounding data resources to perform qualitative and extensive pharma reports. The area under study involves: biosimilars, medications, orphan drugs, patient-centric disease treatment and healthcare technologies.

In the reports customers will find basic market information on the products and the following takeaways:
  • Leading and emerging trends;
  • Medical enterprises;
  • Critical analysis for best strategies;
  • Multichannel marketing modelling to guide the customers to the right channels and content;
  • Key success factors and opportunities for pharma industry;
  • Pharma sales analysis; etc.
FirstWord helps you stay competitive, get 5 year forecast and improve productive efficiency. To acquire measurable and sufficient outcome it is vital to use FirstWord consulting service.

Research Reports By FirstWord

Found 386 publications
Rheumatoid Arthritis: KOL Insight US$ 7,900.00 Mar, 2016
NPS+ HIV (US) US$ 2,495.00 Mar, 2016
NPS+ HIV (EU5) US$ 2,495.00 Mar, 2016
NPS+ Renal Cell Carcinoma (US) US$ 2,495.00 Feb, 2016
NPS+ Renal Cell Carcinoma (EU5) US$ 2,495.00 Feb, 2016
Biosimilars in Oncology: KOL Insight US$ 7,900.00 Jan, 2016
Pharma Marketing 2020 (2016) US$ 695.00 Jan, 2016
NPS+ Rheumatoid Arthritis (EU5) US$ 2,495.00 Dec, 2015
NPS+ Multiple Sclerosis (US) US$ 2,495.00 Dec, 2015
NPS+ Multiple Sclerosis (EU5) US$ 2,495.00 Dec, 2015
NPS+ Type 2 Diabetes Mellitus (US) US$ 2,495.00 Dec, 2015
Ulcerative Colitis: KOL Insight US$ 7,495.00 Dec, 2015
MSL Metrics: Measuring Success US$ 595.00 Dec, 2015
NPS+ Type 2 Diabetes Mellitus (EU5) US$ 2,495.00 Dec, 2015
NPS+ Rheumatoid Arthritis (US) US$ 2,495.00 Dec, 2015
Prostate Cancer: KOL Insight US$ 7,495.00 Nov, 2015
Malignant Melanoma: KOL Insight US$ 7,495.00 Nov, 2015
Biosimilars: Regulatory Outlook US$ 2,100.00 Nov, 2015
Cancer Immunotherapy: Payer Insight US$ 7,495.00 Oct, 2015
Multiple Sclerosis: KOL Insight US$ 7,495.00 Oct, 2015
1 2 3 4 5 ... 8
Skip to top

News & Press-Releases by FirstWord